Acrivon Therapeutics, Inc. ACRV 深 沪
已收盘 02-06 16:00:00 美东时间
1.68
+0.080
+5.00%
华盛通- 最 高3.56
- 今 开1.65
- 成交量 43.12万股
- 最 低 1.57
- 昨 收 1.60
- 总市值 0
- 52周最高 6.08
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 1.05
- 委 比 -53.37%
- 总股本 --
- 历史最高 25.47
- 量 比 0.83
- 振 幅 124.38%
- 历史最低 1.05
- 每 手 1
- 风险率 1.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Market-Moving News for January 8th
ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Accelerates ACRV: 38% | Acrivon Therapeutics Announces Update On ACR-368 Program, Reports Initial Clinical
01-08 20:35
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of AZZ Inc (NYSE:AZZ) rose in pre-market trading after the company repor...
01-08 17:25
Acrivon Therapeutics Q3 EPS $(0.47) Beats $(0.61) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.61) by 22.57 percent. This is a 20.34 percent increase over losses of $(0.59) per share
2025-11-14 05:13
Reported Saturday, Acrivon Therapeutics Reports ACR-368 Phase 2 Endometrial Cancer Data At ESMO, Advances ACR-2316 Ahead Of Schedule, And Updates On AP3 Interactome Progress
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically
2024-09-16 16:46
